Bellicum Pharmaceuticals, Inc. (BLCM): Price and Financial Metrics
GET POWR RATINGS... FREE!
BLCM Stock Summary
- For BLCM, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
- With a year-over-year growth in debt of -100%, Bellicum Pharmaceuticals Inc's debt growth rate surpasses only 0% of about US stocks.
- As for revenue growth, note that BLCM's revenue has grown 1,140% over the past 12 months; that beats the revenue growth of 99.13% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Bellicum Pharmaceuticals Inc, a group of peers worth examining would be CNCE, DTIL, NRIX, SGMO, and IDYA.
- Visit BLCM's SEC page to see the company's official filings. To visit the company's web site, go to www.bellicum.com.
BLCM Valuation Summary
- BLCM's EV/EBIT ratio is 0.7; this is 97.61% lower than that of the median Healthcare stock.
- Over the past 82 months, BLCM's price/sales ratio has gone down 283.7.
- Over the past 82 months, BLCM's price/earnings ratio has gone up 71.
Below are key valuation metrics over time for BLCM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BLCM | 2021-08-31 | 21.2 | -1.8 | 5.7 | 0.7 |
| BLCM | 2021-08-30 | 21.7 | -1.8 | 5.9 | 0.8 |
| BLCM | 2021-08-27 | 22.6 | -1.9 | 6.1 | 1.0 |
| BLCM | 2021-08-26 | 22.3 | -1.9 | 6.0 | 0.9 |
| BLCM | 2021-08-25 | 21.9 | -1.8 | 5.9 | 0.9 |
| BLCM | 2021-08-24 | 23.3 | -2.0 | 6.3 | 1.2 |
BLCM Growth Metrics
- Its year over year net income to common stockholders growth rate is now at 55.66%.
- Its 3 year price growth rate is now at -66.52%.
- The year over year cash and equivalents growth rate now stands at -60.81%.
The table below shows BLCM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 6.2 | -23.106 | -9.705 |
| 2021-09-30 | 6.2 | -30.453 | 6.078 |
| 2021-06-30 | 1.2 | -42.263 | 4.427 |
| 2021-03-31 | 0.5 | -48.688 | -36.565 |
| 2020-12-31 | 0.5 | -56.65 | -7.722 |
| 2020-09-30 | 5.133 | -56.009 | -67.57 |
BLCM Price Target
For more insight on analysts targets of BLCM, see our BLCM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.50 | Average Broker Recommendation | 2 (Hold) |
BLCM Stock Price Chart Interactive Chart >
BLCM Price/Volume Stats
| Current price | $1.55 | 52-week high | $4.04 |
| Prev. close | $1.55 | 52-week low | $1.34 |
| Day low | $1.54 | Volume | 13,400 |
| Day high | $1.75 | Avg. volume | 44,808 |
| 50-day MA | $1.79 | Dividend yield | N/A |
| 200-day MA | $2.05 | Market Cap | 13.35M |
Bellicum Pharmaceuticals, Inc. (BLCM) Company Bio
Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The company was founded in 2004 and is based in Houston, Texas.
Latest BLCM News From Around the Web
Below are the latest news stories about Bellicum Pharmaceuticals Inc that investors may wish to consider to help them evaluate BLCM as an investment opportunity.
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology ConferenceHOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A corporate presentation is scheduled for Thursday, January 27, 2022 at 4 p.m. ET / 1 p.m. PT. A live webcast of the presentation will be available from the Investor Relations section of the company w |
Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.95 and traded as low as $1.67. Bellicum Pharmaceuticals shares last traded at $1.69, with a volume of 149,038 shares traded. The company has a market cap of $14.19 [] The post Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 appeared first on ETF Daily News . |
Bellicum Regains Compliance with Nasdaq Continued Listing RequirementsHOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders equity of at least $2.5 million for continued listing of the companys common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the companys recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent... |
Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and Myovant (NYSE: MYOV), a publicly listed company that is majority-owned by Sumitovant, achieved significant clinical, regulatory and commercial milestones during the company's second quarter of fiscal year 2021 ending in October. |
Bellicum Reports Positive Interim Data From Phase 1/2 GoCAR-T Trials - Quick Facts(RTTNews) - Bellicum Pharmaceuticals, Inc. (BLCM) reported positive interim data from ongoing phase 1/2 GoCAR-T clinical trials, including a confirmed partial response in the first cohort of mCRPC patients treated in the clinical trial for BPX-601. Charity Scripture, Chief Development Officer of Bellicum, said: "The early clinical activity we |
BLCM Price Returns
| 1-mo | -21.97% |
| 3-mo | -10.40% |
| 6-mo | -16.22% |
| 1-year | -43.64% |
| 3-year | -94.32% |
| 5-year | -98.77% |
| YTD | 4.03% |
| 2021 | -57.79% |
| 2020 | -72.64% |
| 2019 | -55.82% |
| 2018 | -65.28% |
| 2017 | -38.25% |
Continue Researching BLCM
Want to see what other sources are saying about Bellicum Pharmaceuticals Inc's financials and stock price? Try the links below:Bellicum Pharmaceuticals Inc (BLCM) Stock Price | Nasdaq
Bellicum Pharmaceuticals Inc (BLCM) Stock Quote, History and News - Yahoo Finance
Bellicum Pharmaceuticals Inc (BLCM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...